Can Compounded Semaglutide Make You Tired? Understanding Fatigue and Weight Loss Medication

Last reviewed: June 11, 2026

Last updated: June 11, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Fatigue is a documented adverse reaction of semaglutide, so yes, it can. In the pooled adult weight-reduction trials reported in the Wegovy prescribing information, fatigue — a category that includes asthenia — occurred in 11% of patients on semaglutide 2.4 mg versus 5% on placebo. The Ozempic label lists fatigue among adverse reactions occurring at a frequency above 0.4%. One important caveat applies to the compounded version specifically: compounded preparations do not carry FDA-approved labeling of their own, so the adverse reaction data comes from the approved products that share the active moiety.

What the Numbers Actually Show

The Wegovy adverse reaction table covers events reported in at least 2% of treated adults and more frequently than placebo, drawn from trials with 2,116 patients on semaglutide 2.4 mg and 1,261 on placebo. Fatigue appears at 11% versus 5%.

For scale, the same table reports nausea at 44% versus 16%, diarrhea at 30% versus 16%, vomiting at 24% versus 6%, constipation at 24% versus 11%, headache at 14% versus 10% and dizziness at 8% versus 4%. Fatigue is real but sits well below the gastrointestinal reactions that dominate the profile.

Why an 11% Versus 5% Difference Matters

The placebo rate is the useful part. Five percent of people in these trials reported fatigue while receiving no active drug at all, which tells you that a meaningful share of fatigue in anyone starting a weight-management program has nothing to do with the medication.

The difference between the two arms — roughly six percentage points — is the part attributable to the drug in that population. Framing it that way is more useful than either dismissing fatigue or treating it as inevitable.

Plausible Contributors Beyond the Drug Itself

The labeled indications specify use in combination with a reduced-calorie diet and increased physical activity, and in the trials participants received instruction for an approximately 500 kcal/day deficit. A sustained energy deficit is itself a plausible contributor to feeling tired, and it is part of the intervention rather than a side effect of it.

Reduced intake can also affect hydration and nutrient intake, particularly alongside the nausea and vomiting that occur at high rates in this class. The label warns separately about acute kidney injury due to volume depletion and instructs monitoring of renal function in patients reporting adverse reactions that could lead to it.

When Fatigue Should Prompt a Call Rather Than Patience

Some causes of fatigue on this class are not benign and are specifically addressed in the labeling. Hypoglycemia is one: the label warns that concomitant use with insulin or an insulin secretagogue may increase the risk of hypoglycemia, including severe hypoglycemia, and directs that all patients be informed of the risk and educated on signs and symptoms.

Persistent vomiting or diarrhea leading to volume depletion is another, as is any new symptom that accompanies the fatigue. None of that is a self-assessment. It is a reason to contact the prescriber, who can distinguish among causes that look identical from the outside.

The Compounded Caveat Is Real

Compounded semaglutide is not an FDA-approved finished product. As the FDA states, the agency does not review compounded drugs for safety, effectiveness or quality before they are marketed, and there is no approved labeling or trial dataset specific to any compounded preparation.

The FDA has also reported adverse events that may relate to dosing errors with compounded injectable semaglutide, including patients measuring and self-administering incorrect doses and clinicians miscalculating doses, and reports that may relate to prescribing beyond approved labeling. If new fatigue coincides with a dose change, that is worth raising promptly.

What to Tell a Prescriber

Useful detail: when it started relative to starting the medication or changing dosage, whether it follows the injection in a pattern, what else changed at the same time, whether you are eating and drinking normally, and what other medications and supplements you take.

That is the information that lets a clinician separate an expected adjustment from something requiring action. PlexusDx protocols include a prescriber relationship for exactly this reason, with medications dispensed from licensed 503A compounding pharmacies.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

How common is fatigue with semaglutide?

In the pooled adult weight-reduction trials reported in the Wegovy prescribing information, fatigue — a category that includes asthenia — occurred in 11% of patients treated with semaglutide 2.4 mg versus 5% of those on placebo. The Ozempic label separately lists fatigue among adverse reactions occurring at a frequency greater than 0.4%. Gastrointestinal reactions occur far more frequently.

Why did 5% of placebo patients report fatigue too?

Because fatigue is common in the general population and common in anyone starting a structured weight-management program. In these trials, all participants received instruction for an approximately 500 kcal/day deficit and physical activity counseling. The difference between the treated and placebo arms, roughly six percentage points, is what the data attribute to the drug in that population.

Could the calorie deficit be causing the tiredness?

It is a plausible contributor. Every labeled indication specifies use in combination with a reduced-calorie diet and increased physical activity, and trial participants were instructed to maintain approximately a 500 kcal/day deficit. Reduced intake can also affect hydration and nutrient intake, particularly alongside nausea or vomiting, which occur at high rates in this drug class.

When should fatigue be reported to a prescriber?

Promptly, especially if it is persistent, worsening, or accompanied by other symptoms. The labeling warns that concomitant use with insulin or an insulin secretagogue may increase hypoglycemia risk, including severe hypoglycemia, and separately warns about acute kidney injury due to volume depletion in patients with adverse reactions such as vomiting or diarrhea. Those causes require clinical assessment.

Does compounded semaglutide have its own side effect data?

No. Compounded preparations are not FDA-approved finished products and carry no approved labeling or trial dataset of their own; the agency does not review compounded drugs for safety, effectiveness or quality before marketing. Available adverse reaction figures come from the approved products that share the active moiety. The FDA has separately reported adverse events that may relate to dosing errors with compounded products.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.